Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. ("Poseida"), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that preclinical data on P-PSMA-101, the company's PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held November 8-12, 2017 in National Harbor, Maryland.

"P‐PSMA‐101 is a CAR-T cell therapeutic that exhibits a persistently high percentage of stem cell memory T-cells and mediates durable anti‐solid tumor efficacy that surpasses previously established anti‐PSMA CAR T‐cell therapy in several in vivo models," said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida. "Future efforts will continue towards clinical application of P‐PSMA‐101 in patients with metastatic castrate resistance prostate cancer."

The following study will be presented:

Presentation Title: PSMA‐specific CARTyrin T‐stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model
Presenter: Jenessa Smith, Ph.D., Poseida Therapeutics
Date and Time: 12:30.-2:00 p.m. and 6:30-8:00 p.m., Saturday, November 11, 2017

Abstracts are available online at the SITC conference website. Following the presentation on November 11, a poster presentation will be available on the publications page of Poseida's website at www.poseida.com/publications.

About P-PSMA-101

P-PSMA-101 is a CAR-T immunotherapy designed to supercharge a patient's own T cells to safely and effectively eliminate tumor cells carrying prostate-specific membrane antigen (PSMA), which is expressed on the majority of prostate cancer cells. P-PSMA-101 employs a PSMA-specific Centyrin™ binding domain and is engineered using a non-viral gene delivery system called the piggyBac™ DNA Modification System, which leverages the technology's capability to deliver 30 times more cargo than traditional virus-based CAR T-cell modification systems. P-PSMA-101 has demonstrated potent anti-tumor activity, persistent and durable response, significant T-cell memory, a high concentration of P-PSMA-101 modified T-cells and no T-cell exhaustion. A unique feature of P-PSMA-101 and other Poseida CAR-T products is their exceptionally high percentage of stem cell memory T cells, which has been shown in preclinical studies to lead to unprecedented durability of response without re-administration of treatment.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene therapy technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for cancer, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene therapy technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE).  For more information, visit www.poseida.com.

Corporate Communications Contact:
Jason Spark
Canale Communications

To read more Press Release articles, click here.